In order to develop eective vaccine products against human cancer, we are interested in identifying genes over-expressed in tumor cells. Through a combination of cDNA library subtraction and microarray technology, we identi®ed seventeen genes preferentially expressed in lung squamous cell carcinoma, including four novel genes. To date, expression pro®les of these genes were con®rmed by Northern and/or real-time analysis, and several genes were also found to be expressed in head and neck squamous tumors. Thus, these combined methods represent a high throughput approach for identifying tumor speci®c genes. Furthermore, the report of characterization on these genes will allow them to be exploited for their diagnostic, prognostic, and therapeutic potentials including immunotherapy and antibody based anticancer therapy. Oncogene (2000) 19, 1519 ± 1528.
Introduction
Lung cancer is a leading cause of death among all types of cancers. Approximately, one million people worldwide die from lung cancer each year, while six million people die of all types of cancer. Though the incidence of this disease among men has decreased in recent years, the number of cases in women has increased signi®cantly. As a result, the death rate for woman from lung cancer has surpassed that of breast cancer. There are two major types of lung cancer, nonsmall cell lung carcinoma (NSCLC) which comprises 80% of total incidence, and small cell lung carcinoma (SCLC) which accounts for 20% of all cases. The 5-year survival rate for either category is less than 10%. The NSCLC includes squamous cell carcinoma (LSCC), adenocarcinoma, and large cell carcinoma. Current treatment for NSCLC patients includes surgery if the tumor is con®ned and/or a combination of chemotherapy and radiation therapy. Unfortunately, at the time of lung cancer diagnosis, the tumor has often become disseminated. A lack of dependable markers for early diagnosis and treatment has impeded the management of lung cancer. Although several genes have been reported and tested as diagnostic and prognostic markers for lung cancer, i.e. carcinoembryonic antigen (CEA), urokinase plasminogen activator, squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (CYFRA 21..1) (Morita et al., 1998; Pastor et al., 1997; Brechot et al., 1997) , and PGP 9.5 (Hibi et al., 1999) , there is room for much improvement in this area.
The identi®cation of tumor markers is also important as such markers may be developed as antigens for tumor therapy. To date, melanoma antigens have been isolated primarily through immunological identi®cation (Robbins and Kawakami, 1996) . Using stable or transiently transfected cDNA libraries, antigens that speci®cally stimulated tumor-reactive cytotoxic T-cells have been identi®ed on antigen presenting cells expressing appropriate MHC class I molecules. These melanoma antigens are either tumor-speci®c with normal tissue expression limited to testes and placenta such as MAGE-1 and MAGE-3, or tissue-speci®c with lower level expression in normal melanocytes like gp-100 and MART-1 (Robbins and Kawakami, 1996) . Another well-characterized non-melanoma antigen is Her2/Neu which is not tumor-or tissue-speci®c, but is often over-expressed in breast and ovarian carcinoma. Her2/Neu derived peptides have been shown to be recognized by breast and ovarian cytotoxic T-cells (Peoples et al., 1995; Fisk et al., 1995) . Along this line, we are seeking approaches for identifying genes that are over-expressed in lung tumors. These genes can then be evaluated as potential immunotherapeutic targets as determined by their abilities to generate antigen-speci®c cytotoxic T-cells capable of recognizing tumor cells.
Recent developments in cDNA microarray technology (Shena et al., 1995) have allowed the tissue expression pro®les of thousands of genes to be compared simultaneously (DeRisi et al., 1996 (DeRisi et al., , 1997 Lyer et al., 1999) . The limitation of this technology, however, is that genes with abundant messages will dominate the corresponding cDNAs to be arrayed, limiting the representation of genes expressed at lower levels. To increase the potential for identifying both abundant and less abundant messages expressed in lung tumors, we combined cDNA subtractive methodology with microarray technology. Here we report the identi®cation and characterization of 17 genes that are over-expressed in LSCC relative to normal tissues. To our knowledge, this is the ®rst report of extensive analysis and characterization on a large number of dierentially expressed lung squamous cell carcinoma genes. The report of these genes will facilitate the critical assessment of their diagnostic as well as therapeutic potentials.
Results

Generation and characterization of LSCC specific cDNA libraries
To enrich for genes preferentially expressed in lung squamous cell carcinomas, we have generated three lung squamous tumor speci®c cDNA libraries, referred as LST-S1, LST-S2, and LST-S3 (for details, see Materials and methods). In the LST-S1 subtracted cDNA library, we repeatedly recovered genes such as keratin isoform 6 and 58KD type II keratin. As keratinization is one of the major characteristics of all squamous cell carcinomas, recovery of keratin and keratin related genes is an indication of successful subtraction for enriching genes dierentially expressed in lung squamous tumors. However, the complexity of the library was apparently low, as evident by the repeated isolation of the same clones. To solve this problem, a second subtracted library, LST-S2, was constructed using an additional driver comprised of a pool of ®ve genes that are highly enriched in LST-S1. The LST-S2 library contained *20 000 independent clones. DNA from 300 randomly picked clones was puri®ed and sequenced to estimate the complexity of the LST-S2 library. Among 227 clones sequenced, 114 were unique and 57 were novel (with no EMBL/ Genbank hits). Similarly, LST-S3 was generated using a pool of 20 abundant genes from LST-S1 and LST-S2 as additional driver DNA, and roughly 700 clones were recovered. Sequence analysis of 20 clones revealed eight additional novel clones and only two cDNAs that overlapped with sequences from LST-S2. These results suggest that by including abundant tester-speci®c genes in the driver DNA, we were able to enrich for LSCC speci®c genes that are expressed at lower level, and thus increased the complexity of the subtracted cDNA library.
Identification of LSCC specific antigens
Over 3200 clones from LST-S2 and LST-S3 libraries were subjected to pre-screening by colony hybridization using a pool of the eight most frequently identi®ed genes to minimize the redundancy of the clones to be analysed. Roughly 700 clones were eliminated by this step and the remaining 2500 cDNA clones were PCR ampli®ed. Clones of no insert, small insert (less than 200 bp) as well as multiple inserts were further eliminated and a ®nal number of 2002 cDNA clones were arrayed and 25 sets of these were fabricated. The expression pro®les of these cDNA clones were analysed using 23 pairs of probes, and Table 1 summarizes the probe identity, tissue sources, and the balanced coecient for each pair of probes (Cy3/Cy5, see Materials and methods). The quality of the probes depends on the purity, the integrity and the quantity of the mRNA. In addition, the half-life of Cy3 and Cy5 Cyanine dyes is dierent, and these two dyes may not be incorporated into the probes with equal eciency. As a result, a balanced coecient (Cy3/Cy5) is needed to normalize the hybridization signals for any given pair of probes. This can be achieved in two ways. Ideally, the Cy3 and Cy5 signals can be normalized by hybridizing the same cDNA elements with a pair of probes labeled with Cy3 and Cy5, and reversibly Cy5 and Cy3, respectively. However, this will double the amount of work and the amount of RNA used for probe synthesis which can be very limited. Alterna- 200 ng poly A+ RNA was used to generate a single probe. The RNA was reverse transcribed and labeled with Cy3 or Cy5¯uorescent tagged nucleotides. Balanced coecient is calculated by the¯uorescence ratio of Cy3 to Cy5 using the entire chip clones as references. All tumors listed above are primary tumors except the lung pleural eusion (86 ± 52) is metastatic lung adenocarcinoma. There are four lung squamous tumors, four lung adenocarcinoma specimens, one colon tumor, and a variety of other normal tissues that are either distal matched normal tissues of cancer patients or from commercial source (Clontech, Palo Alto, CA, USA); *, The balanced coecient for this pair of probes is out of linear range and as a result, the dierential expression index is no longer correlating to the¯uorescence intensities. See Figure 2 for details tively, we have chosen to balance the Cy3 and Cy5 signals using the entire cDNA elements as references. Therefore, the balanced coeciency for each pair of probes is a ratio of average¯uorescence intensity between Cy3 and Cy5 signals (see Figure 2 for an example). Since multiple probe pairs were used in this study and each hybridization is an independent experiment with a result of competitive hybridization of the two probes, the¯uorescence signal cannot be compared between probe pairs or chips quantitatively. In other words, quanti®cation is only applied to cDNA elements within the chip using the same pair of probes.
The expression pro®les of all cDNA elements on the chip are illustrated using a lung squamous tumor probe paired with a normal kidney probe ( Figure 1a , probe pair 11) and a lung squamous tumor probe with a matched normal lung probe (Figure 1b, probe pair 20) . A large number of clones (within the triangle areas) were found to be over-expressed in these lung squamous tumors. LSCC speci®c genes were scored based upon their expression in over 50% of lung squamous tumors, as compared with undetectable or limited expression in normal tissues. Upon sequencing analysis, we identi®ed 17 genes dierentially overexpressed in lung squamous cell carcinoma including 13 known genes and four novel cDNA sequences. A list of candidates and their corresponding genes (if known) as well as the frequency of genes recovered is listed in Table 2 . The fact that multiple genes were recovered multiple times independently through microarray technology demonstrates that this methodology is a reliable and reproducible tool for gene discovery.
Expression profile of LSCC specific genes
Shown in Figure 2 is the dual color expression analysis of 17 LSCC genes including four novel candidates. The probe pair number, 1 through 23, is listed on the left of each panel (also refer to Table 1 ). Expression levels in probe wells are illustrated by both color images and the fold of dierential expression. To con®rm the expression pro®le of these genes with other independent methodologies, we examined the expression pro®le of a number of genes using Northern and/or quantitative real-time RT ± PCR analysis. Representative genes analysed by Northern analysis (L513S, L514S, L519S and L520S) and RT ± PCR analysis (L513S, L522S, L524S and L528S) are shown in Figure 1 The scatter plot of¯uorescence intensity of 2002 cDNA clones hybridized with a lung squamous tumor probe (9688T) and a normal kidney probe (CT9) in (a) and with a pair of lung squamous tumor (9681T) and normal lung (9681N) probes, in (b). The cDNA clones within the triangle boxes represent the cDNAs that are dierentially over-expressed in these lung squamous tumors (Table 2) . Furthermore, genes that are dierentially expressed at lower level such as L522S, L524S and L531S were con®rmed by sensitive real-time RT ± PCR assay that are otherwise dicult for Northern analysis (Table 2) . For instance, L513S is over-expressed in three out of four lung squamous tumors by both Northern and RT ± PCR analysis (Figures 3a and 4a) , consistent with what we observed from cDNA microarray data ( Figure  2a ). In addition, L513S is also over-expressed in four out of four head and neck squamous tumors, as revealed by RT ± PCR analysis (Figure 4a ). Importantly, expression of L513S was consistently not detected in either lung adenocarcinoma or a panel of normal tissues including lung, brain, kidney, liver, breast, colon, bronchiole epithelial cells, and pancreas by three independent approaches (Figures 2b, 3a and 4a). Lower level expression of L513S in normal epithelial cell containing tissues such as skin ( Figures  2b and 4a) , esophagus, trachea, and soft pallet ( Figure  4a ), is also well demonstrated. Similarly, L519S is expressed in normal breast and skin besides tumors as shown by cDNA microarray and Northern analysis (Figures 2c and 3c) , as well as indicated by RT ± PCR analysis (Table 2 ). It is noteworthy that inconsistent expression pro®les were observed occasionally for genes that we have analysed. However, we believe that these are largely contributed by sensitivity of the assay and/or quality of individual samples. For instance, expression of L513S and L520S detected in normal skin and/or salivary gland by cDNA microarray analysis was not re¯ected in the Northern blots. This may be due to the lower sensitivity nature of Northern analysis and to the integrity of the RNA sample (notice that the ratio of 28S rRNA and 18S rRNA for the skin sample is 51, an indication of partial degradation). In conclusion, results of Northern analysis on L513S, L514S, L519S and L520S and real-time RT ± PCR analysis on L513S, L522S, L524S and L528S showed consistent correlation with the cDNA microarray data, thus further validating the high throughput approach for identifying dierentially expressed genes using combination of subtraction and cDNA microarray technologies.
Discussion
As discussed earlier in the case of melanoma antigens, we expected to identify genes that were either tumor speci®c or squamous cell speci®c. Based upon the expression pro®le of known genes and the previous studies, they are grouped in three categories: genes that are tissue speci®c (Figure 2a) , genes that are tumor speci®c (Figure 2b ), and genes that are novel ( Figure 2c ). The signi®cance of these results is discussed below and the summary of the discussion is listed in Table 3 .
Tissue-specific genes
Tissue speci®c genes include L529S, L525S, L527S, L513S, L520S and L521S. L529S, L525S and L527S are cytoskeletal components. L513S, L520S and L521S are squamous cell speci®c markers ( (Jamieson et al., 1998) , it remains to be seen if the L529S is a mutated or non-mutated form of connexin 26. L525S is plakophilin 1, a desmosomal protein found in plaque-bearing adhering junctions of skin (Moll et al., 1997) . mRNA for L525S is highly elevated in three out of four lung squamous tumors tested. Expression of L525S in Figure 2 Microarray analysis of potential lung squamous tumor antigens. (a) Shows genes that are squamous tissue speci®c as these genes are also expressed in normal squamous cell containing tissues such as skin (probe pair 1). (b) Illustrates tumor speci®c candidates which include lung squamous tumor speci®c genes and genes that are also found in other tumor targets. (c) denotes the expression pro®le of four novel genes, L514S, L519S, L530S and L531S. In all cases, the data is shown by both color image of hybridization intensities (white being the strongest and dark being the weakest) and the fold of balanced dierential expression between probes in Cy3 and Cy5 channel. The probe pairs are from 1 to 23 (also refer to Table 1 )`+' and`7' indicate the expression being stronger in Cy3 and Cy5 channel, respectively (see Materials and methods for detail). The arrows in both (a) and (b) denotes the probe pair 21 of which the balanced coecient is so distorted (see * in Table 1 ) that the balanced dierential expression number is no longer correlated with the color image
Oncogene LSCC differentially expressed genes T Wang et al normal skin may prevent it from being developed as a therapeutic vaccine due to potential autoimmune responses, although, it could prove useful as a diagnostic marker. To our knowledge, this is the ®rst report of over-expression of plakophilin 1 in LSCC. We have also repeatedly identi®ed keratin 6 isoform and type II 58KD keratin in our initial subtracted library such as LST-S1 (Table 3 ). In addition, we have recovered cytokeratin 13, L527S. As discussed earlier, keratin and keratin-related genes, i.e. CYFRA2.1, have been extensively documented as potential markers for lung cancer (Pastor et al., 1997; Brechot et al., 1997) . Here we show that a variety of keratin related genes are upregulated in LSCC and the overall expression pro®les for these keratin genes are similar to that of L527S. L513S, L520S and L521S are not cytoskeletal components, but appear to be speci®c to squamous cells as they are present in normal skin (Figure 2a ). Both cDNA microarray and Northern analysis show elevated expression of these genes in lung squamous tumors (Figures 2a and 3a,d ), as also revealed by real-time RT ± PCR analysis for L513S (Figure 4a ). L513S encodes a protein that was ®rst isolated as a pemphigus vulgaris antigen using patient autoantibodies (Amagai et al., 1991) . L520S (SPRC) (Robinson et al., 1994) and L521S (SPR1) belong to a family of small proline rich proteins, representing markers for fully dierentiated squamous cells. L521S has recently been described as a speci®c marker for lung squamous tumor (Hu et al., 1998) . Although L520S and L521S have similar expression pro®les in lung squamous tumors, they seem to dier in their normal tissue expression. L520S is up regulated in normal salivary gland whereas expression of L521S is dominant in normal skin ( Figure  3a) . Interestingly, Northern analysis also showed that L520S is highly expressed in esophagus and trachea. These results suggest that L520S and L521S have distinct roles in cell dierentiation and tumorigenicity. 
Tumor-specific genes
The tumor speci®c genes can be subdivided in three groups: cell signaling components (L515S, L524S, L526S), enzymes (L516S, L522S), and shared tumor antigens (L523S, L528S), (see Table 3 ). L515S is moderately expressed in lung squamous tumors and encodes IGF-beta2. Mechanism underlying the elevation of L515S messages are not clear except that secretion of multiple growth factors including IGF-beta2 by a nonsmall cell carcinoma cell line has been documented (Occleston and Walker, 1993) . Parathyroid hormonerelated peptide (PTHrP), L524S, is known to cause humoral hypercalcaemia associated with malignant tumors such as leukemia, prostate and breast cancer. It is also believed that PTHrP is most commonly associated with squamous carcinoma of lung and rarely with lung adenocarcinoma (Davidson et al., 1996) . It is therefore not surprising to see elevated expression of L524S in both lung and head and neck squamous tumors ( Figure  4c ). Finally, L526S is a gene called ATM. Mutations in ATM cause a genetic disorder in humans known as ataxia telangiectasia characterized by immunode®ciency, progressive cerebella ataxia, radiosensitivity, and cancer predisposition (Morgan and Kastan, 1997) . Recent studies have shown that ATM encodes a 350 KD protein containing a PI-3 kinase domain and is required for optimal function of p53 (Khanna et al., 1998) . Speci®cally, ATM activates p53 mediated cell cycle checkpoint through direct binding and phosphorylation of p53. As shown in Figure 2b , over-expression of ATM is observed in all LSCC tested. However, it is not known whether up regulation of ATM is a cause or a result of LSCC. Because 40% of lung cancer is associated with p53 mutations (Hollstein et al., 1991) , it is likely that over-expression of ATM is a result of compensation for loss of p53 function. On the other hand, the expression of ATM seems to be squamous cell speci®c as indicated by its expression in normal skin (see probe pair 1 in Figure  2b ). Importantly, expression of ATM was also detected in a metastatic but not other lung adenocarcinoma (compare probe pairs 3 and 9 with probe pairs 7, 10, 16, 17 and 19) . This result suggests that the ATM gene may also be involved in metastasis. Taking together, the expression pro®le of ATM and its association with p53 suggest that this molecule plays an important role in Figure 4 Real-time RT ± PCR analysis of L513S (a), L522S (b), L524S (c), and L528S (d). Each gene is analysed using an identical panel of 36 cDNA samples comprised of four lung squamous tumors (1 ± 4), one of each lung adenocarcinoma, mesothelioma, and large cell carcinoma (5 ± 7), four head and neck squamous tumors (8 ± 11), ®ve normal lung tissue samples (12 ± 16), and various other normal tissues (17 ± 36). The expression of each gene for each cDNA sample is normalized against internal actin transcripts and is plotted as copies per 1000 pg actin (see Materials and methods for details). Notice that L513S and L528S are much more abundant compared with L522S and L524S tumor biology and makes it an interesting target for studying the mechanism of tumorigenicity of LSCC.
L516S is an aldose reductase homologue and L522S belongs to a class IV alcohol dehydrogenase, ADH7 (Zgombic-Knight et al., 1995) . Similar to L526S, L516S is also up regulated in metastatic, but not in primary lung adenocarcinoma (see probe pairs 3 and 9 and compare with probe pairs 7, 10, 16, 17 and 19), an indication of a potential role in metastasis and/or as a marker for prognosis. Both L516S and L522S are moderately over-expressed in lung squamous tumors as shown in Figures 2 and 4b . Unlike other alcohol dehydrogenases, expression of ADH7 is not detected in liver and is believed to be most eective as a retinol dehydrogenase (Zgombic-Knight et al., 1995) . It will be interesting to see whether the up regulation of these enzymes is associated with the hypoxic status of the tumor.
In the ®nal group, L523S encodes KOC protein which contains RNA-binding motifs (KH domain). It was ®rst isolated as a gene dierentially over-expressed in human pancreatic cancer cell lines and pancreatic cancer tissues (Mueller-Pillasch et al., 1997) . Recently, another novel cytoplasmic protein containing KH domains has been identi®ed as an autoantigen in human hepatocellular carcinoma (Zhang et al., 1999) . Identi®cation of L523S in lung squamous tumor suggests that this gene may be a shared antigen among LSCC, pancreatic cancer, and hepatocellular carcinoma. Similar to L522S, L523S is only moderately overexpressed in LSCC, yet its expression is low in all normal tissue tested ( Figure 2b and Table 3 ). Therefore, both L522S and L523S can be further evaluated for their diagnostic and therapeutic values. Unlike L523S, L528S is highly expressed in two lung squamous tumors with moderate expression in two other squamous tumors, one lung adenocarcinoma (8009T), and some normal tissues including skin, lymph nodes, heart, stomach and lung as shown by cDNA microarray analysis (Figure 2b) . Nevertheless, it is dierentially expressed in lung squamous tumors compared with other tumors and normal tissues (Figure 4d) . NMB gene is similar to the precursor of melanocyte speci®c gene pMEL17 and is reported to be preferentially expressed in melanoma cell lines with low-metastatic potential (Weterman et al., 1995) . Because the human homologue of pMEL17, gp-100 has been validated as a melanoma antigen, isolation of NMB in LSCC suggests that this potentially shared antigen and its associated antibodies could be developed as anti-cancer products.
Expression of LSCC specific genes in head and neck squamous tumors
Head and neck squamous tumors are very similar to LSCC by their microscopic characteristics. We have found that subsets of LSCC speci®c genes such as L513S, L524S are elevated in head and neck squamous tumors whereas others are not (L522S and L528S) as shown in Figure 4 . Although further studies remain to be seen for other LSCC genes identi®ed here, our preliminary results suggest that distinct molecules may be involved in tumorigenicity of these two types of squamous tumors which can potentially be dierentiated on the molecular level.
Comparison with SAGE analysis
Studies have been initiated on NSCLC dierentially expressed genes using Serial Analysis of Gene Expression (SAGE) (Hibi et al., 1998) . A total of 108 000 and 118 000 tags were sequenced from two SAGE libraries comprised of lung squamous tumors and normal bronchial tracheal epithelial cells, respectively, and the results of sequenced tags were compared between tumor and normal SAGE libraries. Over a dozen genes were found to be overexpressed in NSCLC and three of these genes including PGP 9.5, B-myb, and human mutT were con®rmed to be dierentially expressed in lung cancers. Interestingly, these three genes are not overlapping with seventeen genes that we have identi®ed here and this may be due to several factors. First, the uniqueness of the tumor samples between two studies may account for the dierence. Secondly, SAGE analysis is prone to identify moderately to abundantly expressed genes whereas our subtraction strategy was designed to selectively enrich for less abundantly expressed genes and allow us to identify dierentially expressed genes that are expressed at a lower level such as L522S, L524S, and L531S. Finally, our criteria for selecting LSCC speci®c genes may be more stringent than SAGE analysis. This is because our subtractions were performed using a number of dierent normal tissues and candidate genes were selected based on their relatively low level expression in a panel of 23 normal tissues whereas SAGE analysis is limited to one normal epithelial cell type as reference. However, SAGE analysis is less expensive to perform and requires a less sophisticated technology platform. We believe that it is bene®cial to have parallel approaches since they may complement each other as we have already seen here.
In conclusion, we reported using a combination of cDNA library subtraction and microarray analysis for identi®cation and initial characterization of 17 genes preferentially expressed in lung squamous cell carcinoma. Expression pro®les of these genes were con®rmed by Northern and/or real-time RT ± PCR analysis. Protein expression and localization of these genes will be evaluated by immunohistochemistry. Genes that are tumor speci®c such as L522S, L523S, L524S, L526S and L528S will also be tested for their antigenicity and ability to generate T-cell responses. Finally, full-length cDNA isolation for novel candidates, 514S, 519S, L530S and L531S are currently in progress and they should provide us with additional tools for developing lung cancer diagnostic and therapeutic products.
Materials and methods
Tissue and RNA sources
Tumor and some normal tissues used in this study were from Cooperative Human Tissue Network (CHTN), National Disease Research Interchange (NDRI), and Roswell Park Cancer Center.
Construction of a cDNA library using LSCC
A human lung squamous cell carcinoma cDNA library was constructed from poly A + RNA extracted from a pool of two patient tissues using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning Kit (GIBCO BRL Life Technologies, Gaithersburg, MD, USA) with modi®cations. Brie¯y, BstXI/EcoRI adaptors (Invitrogen, San Diego, CA, USA) were used and cDNA was cloned into pcDNA3.1+ vector (Invitrogen) that was digested with BstXI and EcoRI. A total of 2.7610 6 independent colonies were obtained, with 100% of clones having inserts and the average insert size being 2100 base pairs.
Construction of cDNA libraries using normal lung, heart and liver tissues Using the same procedure, a normal human lung cDNA library was prepared with a pool of four lung tissue specimens, and a normal human liver and heart cDNA library was generated from equal amounts of total RNA isolated from heart and liver tissues. The normal lung library contained 1.4610 6 independent colonies, with 90% of clones having inserts and the average insert size being 1800 base pairs. The normal heart and liver cDNA library contained 1.7610 6 independent colonies, with 100% of clones having inserts and the average insert size being 1600 base pairs.
Lung squamous cell carcinoma-specific subtracted cDNA libraries
To enrich for genes preferentially expressed in LSCC, we performed cDNA library subtractions using the above lung squamous cell cDNA library as the tester and normal tissue cDNA libraries as driver, as previously described (Sargent and Dawid, 1983; Duguid and Dinauer, 1990) , with modi®cations. Normal lung, liver and heart cDNAs (40 mg of each) were digested with BamHI and XhoI, followed by phenol-chloroform extraction and ethanol precipitation. The DNA was then labeled with photoprobe long-arm biotin (Vector Laboratories, Burlingame, CA, USA) and the resulting material was ethanol precipitated and dissolved in H 2 O at 2 mg/ml to prepare driver DNA. For tester DNA, 10 mg of lung squamous cell carcinoma cDNA was digested with NotI and SpeI followed by phenol-chloroform extraction and size fractionation using Chroma spin-400 columns (Clontech, Palo Alto, CA, USA). Five mg tester DNA was mixed with 25 mg driver DNA and proceeded for hybridization at 688C by adding equal volume of 26hybridization buer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/ 0.2% sodium dodecyl sulfate). Following hybridization, several rounds of streptavidin treatment and phenol/chloroform extraction were performed to remove biotinlated DNA, both driver DNA and tester DNA hybridizing to driver DNA. The subtracted DNA enriched for tester-speci®c DNA was then hybridized to additional driver DNA for a second round of subtraction. After the second round of subtraction, DNA was precipitated and ligated into pBCSK+plasmid vector (Stratagene, La Jolla, CA, USA) to generate a Lung Squamous Tumor-speci®c Subtracted cDNA library, referred to as LST-S1, LST-S2, LST-S3 etc.
To analyse the subtracted libraries, 20 to 300 clones were randomly picked and plasmid DNA was prepared for sequence analysis with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A and/or Model 377 (Foster City, CA, USA). These sequences were compared to sequences in the GenBank and human EST databases. The redundancy and the complexity of each subtracted cDNA library was then estimated based on the frequency of each unique cDNA recovered. Highly redundant cDNAs were then used as probes to pre-screen the subtracted cDNA libraries to eliminate redundant cDNA fragments from those to be analysed by microarray technology.
Analysis of cDNA expression using microarray technology
A total of 2002 cDNA fragments isolated in LST-S1, LST-S2 and LST-S3 were PCR ampli®ed from individual colonies. Their mRNA expression pro®les in lung tumor, normal lung, and other normal and tumor tissues were examined using cDNA microarray technology (Incyte, Palo Alto, CA, USA) as described (Shena et al., 1995) . In brief, these clones were arrayed onto glass slides as multiple replicas, with each location corresponding to a unique cDNA clone (as many as 10 000 clones can be arrayed on a single slide, or chip). Each chip was hybridized with a pair of cDNA probes that were¯uorescence-labeled with Cy3 and Cy5, respectively. Typically, 200 ng of polyA + RNA was used to generate each cDNA probe. After hybridization, the chips were scanned and the¯uorescence intensity recorded for both Cy3 and Cy5 channels. There were multiple built-in quality control steps. First, the probe quality was monitored using a panel of 18 ubiquitously expressed genes. Secondly, the control plate also had yeast DNA fragments of which complementary RNA was spiked into the probe synthesis for measuring the quality of the probe and the sensitivity of the analysis. Currently, the technology oers a sensitivity of 1 in 100 000 copies of mRNA. Finally, the reproducibility of this technology was ensured by including duplicated control cDNA elements at dierent locations. Further validation of the process was indicated in that several dierentially expressed genes were identi®ed multiple times in the study, and the expression pro®les for these genes are very comparable (not shown).
Northern analysis of LSCC specific genes
Northern blots were done using 20 mg of total RNA for each sample according to standard procedures. Each blot was stained with 0.02% methylene blue to reveal ribosomal RNA before hybridization. Pictures and autographs were scanned and processed through Photoshop 4.0.
Quantitative real-time RT ± PCR analysis of LSCC-specific genes
The quantitative RT ± PCR analysis was performed using 1:he TaqMan TM chemistry provided by Perkin Elmer/ABI (PE Biosystems, Foster City, CA, USA). The TaqMan probe containing a Reporter dye at the 5' end (FAM) and a Quencher dye at the 3' end (TAMRA) (Perkin Elmer/Applied Biosystems Division, Foster City, CA, USA). Target-speci®c PCR ampli®cation results in cleavage and release of the Reporter dye from the Quencher-containing probe by the nuclease activity of AmpliTaq Gold TM (PE Biosystems). Thus,¯uorescence signal generated from released Reporter dye is proportional to the amount of PCR product. To compare the relative level of gene expression in multiple tissue samples, a panel of cDNA was constructed using RNA from interested tissues, and real-time RT ± PCR was performed using gene speci®c primers to quantify the copy number in each cDNA sample. Each cDNA sample was done in duplicate and each reaction repeated in duplicated plates. The ®nal real-time RT ± PCR result is reported as an average of copy number of a gene of interest normalized against the average of actin copy number in each cDNA sample. All RT ± PCR reactions were performed on an ABI PRISM 7700 Detector (PE Biosystems).
